Severe COVID-19 Clinical Trial
Official title:
Comparative Analysis of Clinical Indicators and Imaging Changes of Severe COVID-19
Novel Coronavirus Pneumonia (COVID-19) is the pneumonia caused by the 2019 novel coronavirus infection. Critically ill patients with this disease develop dyspnea and hypoxemia, and even further aggravate acute respiratory distress syndrome, septic shock, coagulation dysfunction, and multiple organ failure. Since February 15, 2020, the 171-member medical team of the Second Affiliated Hospital of Zhejiang University School of Medicine has taken over the Intensive Care Unit of the Cancer Center of the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and the Intensive Care Unit of the West Hospital of Union Hospital to carry out severe and critical care. Treatment of patients with new coronary pneumonia. In clinical practice, combined with the changes in chest CT imaging of severe COVID-19 patients, it has been found that some laboratory indicators of severe patients can effectively judge the clinical prognosis and outcome of patients, but there is no relevant retrospective study with large sample size so far.
Novel Coronavirus Pneumonia (COVID-19) is the pneumonia caused by the 2019 novel coronavirus infection. Critically ill patients with this disease develop dyspnea and hypoxemia, and even further aggravate acute respiratory distress syndrome, septic shock, coagulation dysfunction, and multiple organ failure. Since February 15, 2020, the 171-member medical team of the Second Affiliated Hospital of Zhejiang University School of Medicine has taken over the Intensive Care Unit of the Cancer Center of the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and the Intensive Care Unit of the West Hospital of Union Hospital to carry out severe and critical care. Treatment of patients with new coronary pneumonia. In clinical practice, combined with the changes in chest CT imaging of severe COVID-19 patients, it has been found that some laboratory indicators of severe patients can effectively judge the clinical prognosis and outcome of patients, but there is no relevant retrospective study with large sample size so far. In April 16, 2020, the investigators submitted the research project, comparative analysis of clinical parameters and radiographic changes of severe COVID-19, to human subject research ethics committee of Second Affiliated Hospital, School of Medicine, Zhejiang University. The research process began after the committee for approval in May 2020. In this study, by comparing the changes in chest CT imaging of patients with severe COVID-19, the investigators analyzed the effects of some clinical indicators on the prognosis and outcome of patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
Recruiting |
NCT05256511 -
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
|
||
Completed |
NCT04866082 -
Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
|
||
Recruiting |
NCT05233605 -
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
|
||
Not yet recruiting |
NCT04613986 -
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
|
N/A | |
Recruiting |
NCT05447013 -
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04733833 -
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT04712344 -
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
|
Phase 2 | |
Terminated |
NCT04713176 -
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
|
Phase 3 | |
Recruiting |
NCT04648410 -
Corticosteroids in Severe COVID-19(ASAP-C Study)
|
||
Enrolling by invitation |
NCT06235866 -
Risk Identification of Long-term Complications
|
||
Recruiting |
NCT05254990 -
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT05596617 -
Safety and Efficacy of Medications COVID-19
|
N/A |